Navigation Links
SynCardia Hits Record-Setting 150th Implant of the Total Artificial Heart in 2013
Date:12/11/2013

TUCSON, Ariz., Dec. 11, 2013 /PRNewswire/ -- SynCardia Systems, Inc. continues to set records with the implantation of the year's 150th SynCardia temporary Total Artificial Heart on Nov. 26, 2013. With almost three weeks left in 2013, SynCardia projects beating the 2012 record of 125 implants by 35 additional Total Artificial Hearts, the most patients ever implanted in one year.

(Photo: http://photos.prnewswire.com/prnh/20131211/LA31265)

"The record we are setting in 2013 for SynCardia Total Artificial Heart implants nearly doubles what was then our 2011 record-breaking year of 81 implants," says SynCardia CEO and President Michael P. Garippa.

The new record includes the first patient in the Gulf South Region, the first Nebraska and Florida patients, an Indiana patient who became the 1,200th implant worldwide and the youngest patient, 16, ever to receive a SynCardia Heart powered by the Freedom® portable driver.

This year, the top 10 SynCardia Certified Centers averaged more than eight implants per center. Leading centers include EJK Duisburg, Germany; La Pitié-Salpêtriére in Paris, France; Ege University in Izmir, Turkey, and seven SynCardia Certified Centers in the United States, including Cedars-Sinai Heart Institute and University of Rochester Medical Center.

The Nebraska Medical Center was a leader for implants by first-year SynCardia Certified Centers.

"Surgeons and patients around the world are recognizing the life-saving benefits of the SynCardia Total Artificial Heart," says Garippa. "The SynCardia Heart is becoming the standard of care for end-stage biventricular heart failure." Garippa joined SynCardia as president in July 2010 and became CEO, as well, in May 2011.

The SynCardia Heart is the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart. It is used as a bridge to transplant to a donor heart. Similar to a heart transplant, the SynCardia device replaces both failing heart ventricles and the four heart valves, which eliminate the source and symptoms of end-stage biventricular (both sides) heart failure.

Unlike a donor heart, the SynCardia Heart is immediately available at 93 SynCardia Certified Centers. Thirty-five other medical centers are in the process of certification.

The Freedom portable driver, weighing 13.5 pounds, allows patients to leave the hospital to live at home and their communities. It provides them the freedom to exercise, comfortably sleep at home, enjoy a home-cooked meal and get out in the community, all of which help them get stronger for an eventual donor heart transplant.

CAUTION - The Freedom portable driver is an investigational device, limited by United States law to investigational use.

About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end stage heart failure affecting both sides of the heart (biventricular failure). There have been more than 1,250 implants of the Total Artificial Heart, accounting for more than 335 patient years of life on the device.

Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves. It is the only device that eliminates the symptoms and source of end stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at 93 SynCardia Certified Centers worldwide with 35 others in the process of certification.

The Total Artificial Heart provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

Forbes Ranks SynCardia #69 Among "America's Most Promising Companies"
In its February 2013 issue, Forbes selected SynCardia as one of "America's Most Promising Companies" for the second consecutive year. On the list of 100 privately held, high-growth companies with bright futures, SynCardia was selected #69, moving up eight spots from its #77 ranking last year. See the full list of SynCardia Awards & Recognition.

For additional information, please visit: http://www.syncardia.com
Like SynCardia on Facebook
Follow SynCardia on Twitter – @SynCardia
Connect with SynCardia on LinkedIn


'/>"/>
SOURCE SynCardia Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. SynCardia Posts Record Revenue and Profit in Q1 2012
2. 3 Pediatric Centers that Offer SynCardia Total Artificial Heart Named in Top 10 for "Best Childrens Hospitals"
3. 1st SynCardia Total Artificial Heart Implant Performed in New England
4. 50% of U.S. News & World Reports "Best Hospitals" for Cardiology & Heart Surgery Making the SynCardia Total Artificial Heart Part of Their Toolbox
5. SynCardias Record-Setting Q2 Marks 5th Consecutive Profitable Quarter
6. EJK Duisburg Becomes One of the Most Active SynCardia Certified Centers in Europe
7. SynCardia Total Artificial Heart Patient Featured in U.S. News & World Reports "Best Hospitals" Issue
8. 1st SynCardia Total Artificial Heart Patient Discharged from Ankara University in Turkey
9. University of Washington Leads All SynCardia Certified Centers with 10 Implants of the Total Artificial Heart in 2012
10. Forbes Ranks SynCardia Among "Americas Most Promising Companies" for Second Straight Year
11. SynCardia Total Artificial Heart Patient with End-Stage Renal Failure Recovers Kidney Function after Two Months of Support
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/27/2016)... California (PRWEB) , ... June 27, 2016 , ... "FCPX ... fully customizable inside of Final Cut Pro X," said Christina Austin - CEO of ... unique style. Final Cut Pro X users can now reveal the media ...
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
Breaking Medicine News(10 mins):